Trial Profile
A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 (Dendrimer N-Acetyl-Cysteine) After Intravenous Administration in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Sep 2020
Price :
$35
*
At a glance
- Drugs OP-101 (Primary)
- Indications Adrenoleucodystrophy; Neurological disorders
- Focus Adverse reactions
- Sponsors Orpheris
- 31 Aug 2020 Results presented in an Ashvattha Therapeutics media release.
- 14 Sep 2018 Status changed from recruiting to completed.
- 16 Apr 2018 Status changed from planning to recruiting.